The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.

The p16Ink4/CDKN2, D-type cyclins, their partners Cdk4/Cdk6, and pRb constitute a G1 regulatory pathway commonly targeted in tumorigenesis. Genetic, immunochemical, and functional cell cycle analyses showed abnormalities of this pathway in each of 22 human melanoma cell lines examined. Normal melanocytes and all melanoma lines expressed Cdk4, Cdk6, and cyclins D1 and D3. The tumor suppressors p16Ink4/CDKN2 and pRb were lost in 17 and 4 cases, respectively, due to various genetic mechanisms, including transcriptional block of p16 and nonsense mutations of RB1. Ectopic expression of p16 prevented S-phase entry of Rb+/p16- but not Rb-deficient melanoma lines. The SK29-MEL-1 cell line harboring an R24C mutation in Cdk4 expressed wild-type pRb and overabundant p16, the latter preventing endogenous Cdk6 but not Cdk4 from associating with cyclin D1. Microinjection of cyclin D1-neutralizing antibody arrested the SK29-MEL-1 cells in G1, whereas pl6 did not, indicating that the cyclin D1/Cdk4-R24C complex is required for G1 progression, and the resistance of the complex to p16 in vivo. These data strongly support the candidacy of Cdk4 as a novel proto-oncogene, provide further evidence for the p16-cyclin D/Cdk-pRb pathway as a functional unit, and suggest that deregulation of this checkpoint may represent a common step in the multistep progression of sporadic malignant melanomas.

[1]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Pagano,et al.  Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. , 1994, Oncogene.

[3]  L. Sandkuijl,et al.  Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.

[4]  A. Okamoto,et al.  IS-12 Mutation and altered expression of P16^ in human cancer. , 1995 .

[5]  L. Lerman,et al.  Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. , 1987, Methods in enzymology.

[6]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[7]  J. Bartek,et al.  Unrestricted cell cycling and cancer , 1995, Nature Medicine.

[8]  P. Pollock,et al.  Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. , 1995, Oncogene.

[9]  M. Strauss,et al.  Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. , 1995, Cancer research.

[10]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[11]  A. Hart,et al.  Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. , 1995, Cancer research.

[12]  J. Bartek,et al.  Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.

[13]  R. Weinberg,et al.  Growth suppression by p16ink4 requires functional retinoblastoma protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Bartek,et al.  Enhanced protein stability: a novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells. , 1996, Oncogene.

[15]  A. Arnold,et al.  Cyclins and oncogenesis. , 1993, Biochimica et biophysica acta.

[16]  G. Peters,et al.  Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. , 1995, The EMBO journal.

[17]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[18]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[19]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[20]  V. Stanton,et al.  Use of denaturing gradient gel electrophoresis to study conformational transitions in nucleic acids. , 1992, Methods in enzymology.

[21]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[22]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[23]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.

[24]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[25]  E. Hovig,et al.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.

[26]  J. Bartek,et al.  Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death , 1997, Nature Medicine.

[27]  A. Hogg,et al.  Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing. , 1992, Oncogene.

[28]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[29]  B. Dynlacht,et al.  Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition , 1995, Nature.

[30]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[31]  L. Sandkuijl,et al.  CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple‐mole melanoma (FAMMM) syndrome families , 1995, Melanoma research.

[32]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[33]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[34]  J. Bartek,et al.  DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.

[35]  E. Schuuring,et al.  Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. , 1995, Blood.

[36]  D. Becker,et al.  Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. , 1996, Oncogene.

[37]  J. A. Bishop,et al.  Retinoblastoma, melanoma and the atypical mole syndrome , 1995, The British journal of dermatology.

[38]  A. Kamb,et al.  Cell-cycle regulators and cancer. , 1995, Trends in genetics : TIG.

[39]  J. Bartek,et al.  Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. , 1995, Oncogene.

[40]  J. Shay,et al.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.

[41]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[42]  R. Saxton,et al.  Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice , 2004, Journal of Cancer Research and Clinical Oncology.